Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0NZYC)

Drug Name

KO-539 Drug Info

Synonyms

UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 138497449
CAS Number: CAS 2134675-36-6
TTD Drug ID: DM0NZYC

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Menin-MLL1 interaction (MEN1-KMT2A PPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SNDX-5613	DMCGX9Y	T lymphoblastic leukaemia	2B33.4	Phase 1/2	[3]
JNJ-75276617	DMR5RHG	Haematological malignancy	2B33.Y	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Menin-MLL1 interaction (MEN1-KMT2A PPI)	TT0CZBQ	MEN1_HUMAN-KMT2A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04067336) First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Kura Oncology.
3	Clinical pipeline report, company report or official report of Syndax Pharmaceuticals.
4	Targeting the undruggable: menin inhibitors ante portas. J Cancer Res Clin Oncol. 2023 Sep;149(11):9451-9459.